Neogenomics Inc (NEO) Stock Analysis and Metrics

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001077183

Market Cap 1.08 Bn

P/E -11.00

P/S 1.45

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 11.09

Add ratio to table...

About

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of test results by licensed physicians and molecular experts specializing in pathology and oncology. The company operates a network of cancer‑focused testing laboratories in the United States and the United Kingdom, with CAP‑accredited and CLIA‑certified facilities in Fort Myers Florida; Aliso Viejo and Carlsbad California; Durham North Carolina; Ramsey New Jersey; Houston Texas; and an ISO‑certified,...

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of test results by licensed physicians and molecular experts specializing in pathology and oncology. The company operates a network of cancer‑focused testing laboratories in the United States and the United Kingdom, with CAP‑accredited and CLIA‑certified facilities in Fort Myers Florida; Aliso Viejo and Carlsbad California; Durham North Carolina; Ramsey New Jersey; Houston Texas; and an ISO‑certified, CAP‑accredited full‑service laboratory in Cambridge United Kingdom. NeoGenomics’ mission is to save lives by improving patient care and its vision is to become the world’s leader in cancer testing information and decision support.

NeoGenomics generates revenue through clinical cancer testing, interpretation and consultative services, molecular and NGS testing, MRD testing, comprehensive technical and professional services, third‑party clinical trials and research support, validation laboratory services, and oncology data solutions. Its test portfolio includes cytogenetics, fluorescence in‑situ hybridization, flow cytometry, immunohistochemistry and digital imaging, molecular residual disease testing using next‑generation sequencing and flow cytometry, broad molecular testing panels such as PanTracer and Neo Comprehensive, and morphologic analysis performed by pathologists. These services are sold to healthcare providers, research institutions and pharmaceutical sponsors who require oncology‑focused diagnostic and biomarker data.

The company operates through the following segment:

• Reportable Segment: This segment encompasses a full suite of oncology diagnostic testing and consultative services, including technical components such as cytogenetics, FISH, flow cytometry, IHC and molecular testing, as well as professional components where physicians and molecular experts interpret results and provide consultation. The segment also offers oncology data solutions, validation laboratory services, and support for third‑party clinical trials, serving community‑based pathology and oncology practices, hospital pathology labs, reference labs, academic centers and pharmaceutical companies across the United States and the United Kingdom.

NeoGenomics holds a competitive position in the oncology testing market alongside large national laboratories such as Quest Diagnostics, Laboratory Corporation of America and ARUP, as well as specialized competitors including Guardant Health, Natera, Exact Sciences, Caris Life Science, Tempus AI and Myriad Genetics. The company differentiates itself through superior testing technologies and instrumentation, robust laboratory information systems, rapid turnaround times, a comprehensive test menu that combines technical and professional components, and a national direct sales force trained in cancer genetic testing and consultative selling.

NeoGenomics serves a diverse customer base that includes community‑based pathology and oncology practices, hospital pathology laboratories, reference laboratories, academic medical centers and pharmaceutical companies seeking oncology diagnostic, biomarker and clinical trial support services.

Investment thesis

Bull case

NeoGenomics’ Q4 results demonstrated a 23 percent year over year growth in NGS revenue, a pace that far outstrips the broader NGS market rate, and the segment now represents roughly one third of total clinical revenue. This expansion is driven by successful commercial execution and a strategic focus on high margin tests, reflected in a 5 percent sequential rise in average unit price and a 6 percent volume gain in the same store business. The company’s ability to capture both volume and price upside in the rapidly evolving oncology testing landscape positions it to sustain double digit revenue growth through 2026 and beyond, as management consistently cites NGS as a core growth engine. The ongoing pipeline of new NGS products, with five launches since March 2023 contributing 23 percent of clinical revenue, further underscores the momentum that could translate into incremental top‑line acceleration.
The imminent full clinical launch of RADAR ST, a circulating tumor DNA MRD assay, aligns with an emerging 20 plus billion dollar MRD monitoring market, and management’s early MolDX approval in two indications provides a strong foundation for immediate revenue capture. Although the company forecasts modest single digit million contributions in 2026, the strategic roadmap positions RADAR ST to become a significant driver of both clinical and pharma revenue once additional indications clear reimbursement, with potential upside in 2027 and beyond. The targeted launch in HPV negative head and neck and selected breast cancer sub‑indications leverages a narrow, high value niche that is currently underserved, giving NeoGenomics first‑mover advantage and a higher price lever. Moreover, the ability to bundle RADAR ST with existing therapy‑selection and MRD offerings creates a synergistic platform that can accelerate adoption and reinforce customer stickiness. The company’s disciplined execution of the launch, as evidenced by the planned expansion of oncology sales specialists to cover ENT and other specialists, signals confidence that the timing and scale of market entry will be well‑aligned with revenue guidance.
Pathline’s acquisition, completed last year, is expected to become accretive to profitability beginning 2026, and integration has already expanded the company’s geographic footprint into the third largest cancer market in the country. By leveraging Pathline’s CAP accredited labs, NeoGenomics can scale capacity, reduce turnaround times, and capture higher margin work, all while providing a single vendor solution to community oncologists who prioritize operational simplicity. Management’s transparency regarding the integration roadmap, including phased LIMS consolidation, suggests that operational efficiencies will be realized in late 2026 and early 2027, providing a clear margin improvement trajectory. The acquisition also offers a platform for cross‑selling high margin NGS and MRD tests to existing Pathline customers, potentially accelerating test mix upgrades. This strategic expansion, combined with the company’s existing network, enhances its competitive moat in the community setting, where 80 percent of oncology care is delivered.
The aggressive expansion of the oncology sales force—35 new specialists in 2025 and an additional 25 slated for Q3 2026—has already translated into a 6 percent volume and 7 percent AUP lift in same store revenue, demonstrating the effectiveness of a dedicated field team. Management’s focus on high value tests, coupled with a sustained NPS of 79, indicates strong physician satisfaction and the likelihood of increased test penetration, with 75 percent of new oncologists ordering five or more NeoGenomics tests. As sales specialists mature, their productivity should normalize, allowing the company to capture more volume from high margin modalities such as NGS, MRD, and therapy selection, thereby improving revenue mix and margin. The strategic deployment of specialized oncology representatives, particularly in under penetrated ENT and head and neck segments, positions the company to capitalize on niche opportunities that competitors have largely ignored. Finally, the investment in a field team is a proven lever for scaling, given that NeoGenomics can now deploy resources more efficiently across its broad portfolio.
The planned consolidation of the eight disparate LIMS systems into a single, common platform is poised to deliver incremental workflow efficiencies that will manifest primarily in 2027 and 2028, but initial benefits are already visible in 2026. By streamlining sample tracking, billing, and reporting, the company expects to reduce operating expenses and improve the quality of data analytics, which can feed back into pricing power and margin expansion. Management’s emphasis on early operational efficiency gains, such as the 100 to 120 basis point gross margin improvement forecast for 2026, indicates that the LIMS rollout is integral to the company’s cost discipline and margin strategy. Additionally, a unified LIMS enhances the company’s ability to scale new test modalities quickly, thereby accelerating go to market speed for future launches. The LIMS initiative thus represents a hidden catalyst that could magnify the impact of other growth drivers, such as the RADAR ST launch and Pathline integration.

NeoGenomics’ Q4 results demonstrated a 23 percent year over year growth in NGS revenue, a pace that far outstrips the broader NGS market rate, and the segment now represents roughly one third of total clinical revenue. This expansion is driven by successful commercial execution and a strategic focus on high margin tests, reflected in a 5 percent sequential rise in average unit price and a 6 percent volume gain in the same store business. The company’s ability to capture both volume and price upside in the rapidly evolving oncology testing landscape positions it to sustain double digit revenue growth through 2026 and beyond, as management consistently cites NGS as a core growth engine. The ongoing pipeline of new NGS products, with five launches since March 2023 contributing 23 percent of clinical revenue, further underscores the momentum that could translate into incremental top‑line acceleration.
The imminent full clinical launch of RADAR ST, a circulating tumor DNA MRD assay, aligns with an emerging 20 plus billion dollar MRD monitoring market, and management’s early MolDX approval in two indications provides a strong foundation for immediate revenue capture. Although the company forecasts modest single digit million contributions in 2026, the strategic roadmap positions RADAR ST to become a significant driver of both clinical and pharma revenue once additional indications clear reimbursement, with potential upside in 2027 and beyond. The targeted launch in HPV negative head and neck and selected breast cancer sub‑indications leverages a narrow, high value niche that is currently underserved, giving NeoGenomics first‑mover advantage and a higher price lever. Moreover, the ability to bundle RADAR ST with existing therapy‑selection and MRD offerings creates a synergistic platform that can accelerate adoption and reinforce customer stickiness. The company’s disciplined execution of the launch, as evidenced by the planned expansion of oncology sales specialists to cover ENT and other specialists, signals confidence that the timing and scale of market entry will be well‑aligned with revenue guidance.
Pathline’s acquisition, completed last year, is expected to become accretive to profitability beginning 2026, and integration has already expanded the company’s geographic footprint into the third largest cancer market in the country. By leveraging Pathline’s CAP accredited labs, NeoGenomics can scale capacity, reduce turnaround times, and capture higher margin work, all while providing a single vendor solution to community oncologists who prioritize operational simplicity. Management’s transparency regarding the integration roadmap, including phased LIMS consolidation, suggests that operational efficiencies will be realized in late 2026 and early 2027, providing a clear margin improvement trajectory. The acquisition also offers a platform for cross‑selling high margin NGS and MRD tests to existing Pathline customers, potentially accelerating test mix upgrades. This strategic expansion, combined with the company’s existing network, enhances its competitive moat in the community setting, where 80 percent of oncology care is delivered.
The aggressive expansion of the oncology sales force—35 new specialists in 2025 and an additional 25 slated for Q3 2026—has already translated into a 6 percent volume and 7 percent AUP lift in same store revenue, demonstrating the effectiveness of a dedicated field team. Management’s focus on high value tests, coupled with a sustained NPS of 79, indicates strong physician satisfaction and the likelihood of increased test penetration, with 75 percent of new oncologists ordering five or more NeoGenomics tests. As sales specialists mature, their productivity should normalize, allowing the company to capture more volume from high margin modalities such as NGS, MRD, and therapy selection, thereby improving revenue mix and margin. The strategic deployment of specialized oncology representatives, particularly in under penetrated ENT and head and neck segments, positions the company to capitalize on niche opportunities that competitors have largely ignored. Finally, the investment in a field team is a proven lever for scaling, given that NeoGenomics can now deploy resources more efficiently across its broad portfolio.
The planned consolidation of the eight disparate LIMS systems into a single, common platform is poised to deliver incremental workflow efficiencies that will manifest primarily in 2027 and 2028, but initial benefits are already visible in 2026. By streamlining sample tracking, billing, and reporting, the company expects to reduce operating expenses and improve the quality of data analytics, which can feed back into pricing power and margin expansion. Management’s emphasis on early operational efficiency gains, such as the 100 to 120 basis point gross margin improvement forecast for 2026, indicates that the LIMS rollout is integral to the company’s cost discipline and margin strategy. Additionally, a unified LIMS enhances the company’s ability to scale new test modalities quickly, thereby accelerating go to market speed for future launches. The LIMS initiative thus represents a hidden catalyst that could magnify the impact of other growth drivers, such as the RADAR ST launch and Pathline integration.

Bear case

Non clinical (pharma) revenue, which constitutes less than six percent of total business, is projected to continue eroding at a mid to upper five percent to ten percent rate in 2026, and management explicitly warns that a return to growth in this segment will not materialize until 2027. This sustained contraction reduces the company’s diversification, leaving it heavily reliant on clinical testing revenue, which is more vulnerable to payer and regulatory headwinds. The continued decline also signals that NeoGenomics is not effectively monetizing its pharmaceutical relationships, potentially due to competitive pricing pressure or limited product relevance. Consequently, the loss of a non clinical revenue stream could expose the company to greater revenue volatility and erode profitability if clinical growth falters. This risk is understated in current guidance, which emphasizes clinical upside without fully accounting for the persistent pharma erosion.
The company’s sequential volume growth dipped in Q4 2025 and is expected to remain negative in Q1 2026 as it intentionally exits low value contracts; management has openly acknowledged a flat or slightly declining year over year volume trend until the back half of 2026. This operational pivot, while aimed at improving mix and AUP, creates a short term revenue drag that could strain margin targets, especially if high margin test uptake is slower than projected. Investors may overestimate the speed of the mix shift, underestimating the possibility of a prolonged period of volume stagnation that could depress revenue growth in the near term. The company’s reliance on a narrow set of high margin tests also raises the risk that any slowdown in adoption or payer coverage could stall the anticipated lift in top line. This scenario highlights a structural risk that the guidance does not fully reflect.
Management explicitly identified extreme weather events as a risk that could negatively impact Q1 2026 clinical volumes and revenue, a risk that has already manifested in the quarter with office closures and appointment rescheduling. While the company adjusted its guidance to incorporate this headwind, the severity and duration of such weather disruptions are uncertain, and repeated or severe events could compound the volume dip. The company’s guidance for 2026 assumes a modest 10 percent growth in Q1, but if weather conditions deteriorate further or if the healthcare system remains cautious, the company may fall short of this target, compressing EBITDA and margin growth. This unquantified risk is a significant vulnerability that could undermine the projected 27 to 31 percent EBITDA expansion.
The revenue upside from RADAR ST and Pantracer liquid (LBX) is heavily contingent on pending MolDX submissions and Medicare coverage decisions; management has admitted that approvals for additional indications are still pending and could be delayed. If these submissions are rejected or delayed beyond the forecasted timeline, the projected mid single digit million contribution for 2026 could fall short, eroding both revenue and margin assumptions. Moreover, the company’s guidance for 2026 is based on a best case scenario where additional indications are approved in the second half of the year, which is an optimistic assumption given the historical 12 month turnaround for MolDX decisions. This regulatory uncertainty represents a hidden catalyst that could blunt the expected revenue acceleration.
The integration of Pathline and the LIMS consolidation are capital intensive and operationally complex initiatives; management’s disclosure of a phased rollout and the mention of operational disruptions suggests the potential for cost overruns and short term efficiency losses. Early integration challenges could offset the expected gross margin improvements, especially if staffing or data migration issues arise, leading to higher operating expenses and margin compression. Investors may underestimate the integration cost, particularly given the company’s relatively large balance sheet, which could absorb short term losses but also limit the flexibility to respond to other market shocks. The risk of integration delays could therefore widen the gap between projected and actual profitability, undermining the company’s growth narrative.

Non clinical (pharma) revenue, which constitutes less than six percent of total business, is projected to continue eroding at a mid to upper five percent to ten percent rate in 2026, and management explicitly warns that a return to growth in this segment will not materialize until 2027. This sustained contraction reduces the company’s diversification, leaving it heavily reliant on clinical testing revenue, which is more vulnerable to payer and regulatory headwinds. The continued decline also signals that NeoGenomics is not effectively monetizing its pharmaceutical relationships, potentially due to competitive pricing pressure or limited product relevance. Consequently, the loss of a non clinical revenue stream could expose the company to greater revenue volatility and erode profitability if clinical growth falters. This risk is understated in current guidance, which emphasizes clinical upside without fully accounting for the persistent pharma erosion.
The company’s sequential volume growth dipped in Q4 2025 and is expected to remain negative in Q1 2026 as it intentionally exits low value contracts; management has openly acknowledged a flat or slightly declining year over year volume trend until the back half of 2026. This operational pivot, while aimed at improving mix and AUP, creates a short term revenue drag that could strain margin targets, especially if high margin test uptake is slower than projected. Investors may overestimate the speed of the mix shift, underestimating the possibility of a prolonged period of volume stagnation that could depress revenue growth in the near term. The company’s reliance on a narrow set of high margin tests also raises the risk that any slowdown in adoption or payer coverage could stall the anticipated lift in top line. This scenario highlights a structural risk that the guidance does not fully reflect.
Management explicitly identified extreme weather events as a risk that could negatively impact Q1 2026 clinical volumes and revenue, a risk that has already manifested in the quarter with office closures and appointment rescheduling. While the company adjusted its guidance to incorporate this headwind, the severity and duration of such weather disruptions are uncertain, and repeated or severe events could compound the volume dip. The company’s guidance for 2026 assumes a modest 10 percent growth in Q1, but if weather conditions deteriorate further or if the healthcare system remains cautious, the company may fall short of this target, compressing EBITDA and margin growth. This unquantified risk is a significant vulnerability that could undermine the projected 27 to 31 percent EBITDA expansion.
The revenue upside from RADAR ST and Pantracer liquid (LBX) is heavily contingent on pending MolDX submissions and Medicare coverage decisions; management has admitted that approvals for additional indications are still pending and could be delayed. If these submissions are rejected or delayed beyond the forecasted timeline, the projected mid single digit million contribution for 2026 could fall short, eroding both revenue and margin assumptions. Moreover, the company’s guidance for 2026 is based on a best case scenario where additional indications are approved in the second half of the year, which is an optimistic assumption given the historical 12 month turnaround for MolDX decisions. This regulatory uncertainty represents a hidden catalyst that could blunt the expected revenue acceleration.
The integration of Pathline and the LIMS consolidation are capital intensive and operationally complex initiatives; management’s disclosure of a phased rollout and the mention of operational disruptions suggests the potential for cost overruns and short term efficiency losses. Early integration challenges could offset the expected gross margin improvements, especially if staffing or data migration issues arise, leading to higher operating expenses and margin compression. Investors may underestimate the integration cost, particularly given the company’s relatively large balance sheet, which could absorb short term losses but also limit the flexibility to respond to other market shocks. The risk of integration delays could therefore widen the gap between projected and actual profitability, undermining the company’s growth narrative.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	27,360.50 Bn	42.27	7,256.31	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	166.69 Bn	24.59	3.69	43.16 Bn
3	DHR	Danaher Corp /De/	116.47 Bn	31.82	4.70	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.38 Bn	38.84	9.53	0.83 Bn
5	A	Agilent Technologies, Inc.	32.06 Bn	24.90	4.54	0.30 Bn
6	IQV	Iqvia Holdings Inc.	28.74 Bn	20.99	1.73	15.83 Bn
7	NTRA	Natera, Inc.	27.83 Bn	-121.42	11.13	0.02 Bn
8	ILMN	Illumina, Inc.	21.92 Bn	25.95	4.99	1.49 Bn

Research Tools

Neogenomics Inc (NASDAQ: NEO)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Neogenomics Inc (NASDAQ: NEO)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password